119 research outputs found
Can we use indicator-based farm sustainability assessment tools for the WEFE Nexus?
No full textFair and safe allocation of natural resources for the Euro-Mediterranean area, especially for semi-arid regions, strongly relies on the adoption of WEFE (Water Energy Food Ecosystem) Nexus strategies. Transitioning to WEFE Nexus requires novel quantifiable assessment for interlinked analysis of the four WEFE sectors. Several indicator-based tools exist for agricultural sustainability at the farm scale. This contribution investigates on the application of such tools in relation for WEFE Nexus approaches. The IDEA method was selected for extending its applicability as a novel WEFE Nexus indicator toolkit and the following challenges are identified: (1) some WEFE aspects need to be reinforced in order to expand the scope beyond the actual agro-ecological focus; (2) the application at the farm scale needs to be articulated with larger scales where the WEFE Nexus displays emerging consistencies; (3) Nexus interactions, trade-offs and synergies could be further accounted for. These three challenges help identify how the IDEA indicator-based tool could be adapted to assimilate the WEFE Nexus approach, and so to allow applications in new agro-hydrological contexts.</p
DS_10.1177_0022034518798804 – Supplemental material for A Prospective, Controlled, Multicenter Study to Evaluate the Clinical Outcome of Implant Treatment in Women with Osteoporosis/Osteopenia: 5-Year Results
No full textSupplemental material, DS_10.1177_0022034518798804 for A Prospective, Controlled, Multicenter Study to Evaluate the Clinical Outcome of Implant Treatment in Women with Osteoporosis/Osteopenia: 5-Year Results by A. Temmerman, L. Rasmusson, A. Kübler, A. Thor, J. Merheb and M. Quirynen in Journal of Dental Research</p
Diabetes insipidus and thrombocytosis as the presenting symptoms of acute myeloblastic leukemia with monosomy 7 [7]
No full text[No abstract available]DELACHAPELLE A, 1987, EUR J HAEMATOL, V39, P404; KIMMEL DW, 1983, CANCER, V52, P2355, DOI 10.1002-1097-0142(19831215)52:122355::AID-CNCR28205212323.0.CO;2-J; LASTARZA R, 1994, HAEMATOLOGICA, V79, P356; Lavabre-Bertrand T, 2001, EUR J HAEMATOL, V66, P66, DOI 10.1034-j.1600-0609.2001.00346.x76
Prevalence and determinants of albuminuria in a cohort of diabetic patients in Lebanon
No full textBACKGROUND AND OBJECTIVES: Few data are available on the extent of albuminuria in diabetic populations in the Middle East generally and in Lebanon specifically. We conducted this study to determine the prevalence of albuminuria and its major risk factors in a cohort of diabetic patients in Lebanon. PATIENTS AND METHODS: Diabetic patients followed in the outpatient department at the American University of Beirut Medical Center (AUBMC) were included in a prospective observational study. AUBMC is a tertiary referral center and the outpatient department typically handles patients of low socioeconomic status with advvanced disease. Patients were classified according to their urinary albumin-to-creatinine ratio (ACR) as having normoalbuminuria (ACR30 mg-g creatinine), microalbuminuria (ACR=30 to 300 mg-g creatinine), or macroaalbuminuria (ACR =300 mg-g creatinine). The three groups were compared to analyze the association between albuminuria and its risk factors. In addition, independent predictors of albuminuria were determined using multivariate logistic regression and presented as an odds ratio. RESULTS: Microalbuminuria and macroalbuminuria were present in 33.3percent and 12.7percent of 222 patients (mean age 56.4 years, mean deviation of diabetes 8.6 years, 58.7percent women, 43.8percent obese), respectively. Factors significcantly associated with microalbuminuria included glycemic control, insulin use, and total and LDL cholesterol. Those associated with macroalbuminuria included in addition to glycemic control and insulin use, duration of diabetes, hypertension, elevated mean arterial pressure (MAP), and presence of neuropathy, retinopathy and peripheral vascular disease by bivariate analysis. Only glycemic control was an independent risk factor for both in addition to MAP and retinopathy for macroalbuminuria by multivariate analysis. CONCLUSION: Albuminuria is highly prevalent among this cohort of diabetic patients in Lebanon. Both glycemmic control and blood pressure need to be better targeted in its management. © Annals of Saudi Medicine.Adler AI, 2003, KIDNEY INT, V63, P225, DOI 10.1046-j.1523-1755.2003.00712.x; Amos A F, 1997, Diabet Med, V14 Suppl 5, pS1; BAKRIS G, OVERVIEW DIABETIC NE; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056-NEJMoa011161; CHATURVEDI N, 1995, DIABETES CARE, V18, P785, DOI 10.2337-diacare.18.6.785; de Boer IH, 2007, J AM SOC NEPHROL, V18, P235, DOI 10.1681-ASN.2006040394; de Zeeuw D, 2004, CIRCULATION, V110, P921, DOI 10.1161-01.CIR.0000139860.33974.28; Ewens KG, 2005, DIABETES, V54, P3305, DOI 10.2337-diabetes.54.11.3305; Gelber RP, 2005, AM J KIDNEY DIS, V46, P871, DOI 10.1053-j.ajkd.2005.08.015; GIRACH A, 2006, INT J CLIN PRACT, V11, P1471; Gross JL, 2005, DIABETES CARE, V28, P164, DOI 10.2337-diacare.28.1.164; HOMMEL E, 1986, DIABETOLOGIA, V29, P211, DOI 10.1007-BF00454877; MARRE M, 1987, BRIT MED J, V294, P1448; Ritz E, 1999, NEW ENGL J MED, V341, P1127, DOI 10.1056-NEJM199910073411506; Rosario Rey F, 2006, Curr Diab Rep, V6, P455, DOI 10.1007-s11892-006-0079-7; SAWICKI PT, 1994, DIABETES CARE, V17, P126, DOI 10.2337-diacare.17.2.126; Taleb N, 2008, BR J DIABETES VASC D, V8, P80, DOI 10.1177-14746514080080020501; Turner RC, 1998, LANCET, V352, P837; Unnikrishnan R, 2007, DIABETES CARE, V30, P2019, DOI 10.2337-dc06-255421
O Fórum de Agricultura Familiar na Região Sul do RS: Agriculturas de base ecológica - Espaços rurais potenciais para o desenvolvimento do turismo rural sustentável no território.
No full textEndocrine dysfunction in a patient with phace syndrome, including port-wine stain of the right periorbital area
No full textObjective: To report a case of PHACE syndrome - Posterior fossa brain abnormalities, Hemangioma (usually facial), Arterial anomalies, Coarctation of the aorta along with cardiac defects, and Eye abnormalities - in a 16-year-old female patient with a port-wine stain of the right periorbital area present since birth in conjunction with hypoplasia of the contralateral internal carotid artery. Methods: Thyroid-stimulating hormone, free thyroxine, and growth hormone (GH) levels were measured, and insulin-induced hypoglycemia and arginine infusion tests were done. Radiologic investigations included sagittal enhanced T1-weighted magnetic resonance imaging of the brain and the pituitary gland as well as computed tomography and magnetic resonance angiography of the head and neck. Results: The patient had a normal karyotype. Her height and weight were below the 5th percentile for her chronologic age, and she had amenorrhea. Laboratory investigations revealed both thyroid and GH deficiencies and confirmed the diagnosis of hypogonadotropic hypogonadism. The imaging studies showed a right intraorbital hemangioma as well as an enhancing mass in the right internal auditory canal at the cerebellopontine angle, consistent with a posterior fossa hemangioma. Initiation of both thyroid and GH replacement therapy improved her growth rate and yielded a good clinical outcome. Conclusion: In patients with facial or neck hemangiomas, PHACE syndrome should be suspected, and brain imaging and cardiac, ophthalmologic, and endocrinologic evaluations are recommended to screen for other potential PHACE abnormalities. © 2010 AACE.Burrows PE, 1998, RADIOLOGY, V207, P601; Coats DK, 1999, OPHTHALMOLOGY, V106, P1739, DOI 10.1016-S0161-6420(99)90350-0; Frieden IJ, 1996, ARCH DERMATOL, V132, P307, DOI 10.1001-archderm.132.3.307; Ghosh A, 2007, INDIAN PEDIATR, V44, P144; Goddard DS, 2006, PEDIATR DERMATOL, V23, P476, DOI 10.1111-j.1525-1470.2006.00287.x; Hangaard J, 1996, J CLIN ENDOCR METAB, V81, P2502, DOI 10.1210-jc.81.7.2502; Heyer GL, 2006, PEDIATR NEUROL, V35, P419, DOI 10.1016-j.pediatrneurol.2006.06.021; Huang SA, 2000, NEW ENGL J MED, V343, P185, DOI 10.1056-NEJM200007203430305; Judd CD, 2007, AM J NEURORADIOL, V28, P25; Lasky JB, 2004, J AAPOS, V8, P495, DOI 10.1016-j.jaapos.2004.06.014; Milosević Maja, 2005, Med Pregl, V58, P410, DOI 10.2298-MPNS0508410M; MULLIKEN JB, 1982, PLAST RECONSTR SURG, V69, P412, DOI 10.1097-00006534-198203000-00002; PASCUALCASTROVIEJO I, 1978, NEURORADIOLOGY, V16, P82; Poindexter G, 2007, PEDIATR NEUROL, V36, P402, DOI 10.1016-j.pediatrneurol.2007.01.017; Rossi A, 2006, AM J NEURORADIOL, V27, P1602; Torer B, 2007, EUR J PEDIATR, V166, P1293, DOI 10.1007-s00431-006-0391-x; Tortori-Donati P, 1999, NEURORADIOLOGY, V41, P369; Weon YC, 2005, AM J NEURORADIOL, V26, P26351
Taurine intestinal absorption and renal excretion test in diabetic patients: A pilot study
No full text[No abstract available]Brons C, 2004, EUR J CLIN NUTR, V58, P1239, DOI 10.1038-sj.ejcn.1601955; Chauncey KB, 2003, ADV EXP MED BIOL, V526, P91; Chesney R W, 1987, Adv Exp Med Biol, V217, P49; De Luca G, 2001, METABOLISM, V50, P60, DOI 10.1053-meta.2001.19432; Di Leo MAS, 2004, AMINO ACIDS, V27, P187, DOI 10.1007-s00726-004-0108-2; FRANCONI F, 1995, AM J CLIN NUTR, V61, P1115; Franconi F, 2004, NEUROCHEM RES, V29, P143, DOI 10.1023-B:NERE.0000010443.05899.2f; GEGGEL HS, 1985, NEW ENGL J MED, V312, P142, DOI 10.1056-NEJM198501173120302; GODEL H, 1984, J CHROMATOGR, V297, P49, DOI 10.1016-S0021-9673(01)89028-2; GOODMAN HO, 1990, BIOCHEM MED METAB B, V43, P1, DOI 10.1016-0885-4505(90)90002-I; Ha HJ, 1999, FREE RADICAL BIO MED, V26, P944, DOI 10.1016-S0891-5849(98)00276-7; Han X, 2006, ACTA PHYSIOL, V187, P61, DOI 10.1111-j.1748-1716.2006.01573.x; Hansen SH, 2001, DIABETES-METAB RES, V17, P330, DOI 10.1002-dmrr.229; HAYES KC, 1975, SCIENCE, V188, P949, DOI 10.1126-science.1138364; HEPNER GW, 1973, J CLIN INVEST, V52, P433, DOI 10.1172-JCI107200; HICKMAN MA, 1992, ADV EXP MED BIOL, V315, P45; Kamata K, 1996, EUR J PHARMACOL, V303, P47, DOI 10.1016-0014-2999(96)00094-5; Kim H, 2006, ADV EXP MED BIOL, V583, P137; Lee YM, 2003, ADV EXP MED BIOL, V526, P75; Levey AS, 1999, ANN INTERN MED, V130, P461; Li CY, 2005, CARDIOVASC DRUG THER, V19, P105, DOI 10.1007-s10557-005-0443-x; Li F, 2006, NEUROBIOL DIS, V22, P669, DOI 10.1016-j.nbd.2006.01.012; MARTENSSON J, 1984, METABOLISM, V33, P425, DOI 10.1016-0026-0495(84)90141-0; MILEI J, 1992, AM HEART J, V123, P339, DOI 10.1016-0002-8703(92)90644-B; PAAUW JD, 1994, AM J CLIN NUTR, V60, P203; Pop-Busui R, 2001, EXP NEUROL, V168, P259, DOI 10.1006-exnr.2000.7591; Rakotoambinina B, 2004, AM J PHYSIOL-ENDOC M, V287, pE255, DOI 10.1152-ajpendo.00333.2003; RUESSHEIM CM, 2007, TAURINE COMPILATION; Shimizu M, 2000, AMINO ACIDS, V19, P605, DOI 10.1007-s007260070010; Vilchis C, 1996, NEUROCHEM RES, V21, P1167, DOI 10.1007-BF02532391; VINTON NE, 1987, PEDIATR RES, V21, P399, DOI 10.1203-00006450-198704000-00016; You JS, 1998, ADV EXP MED BIOL, V442, P163; ZIYADEH FN, 1988, BIOCHIM BIOPHYS ACTA, V943, P43, DOI 10.1016-0005-2736(88)90345-869
Eigenschappen van het kaaksbeen en de invloed op de uitkomst van implantaattherapie.
No full textA large part of the adult population worldwide is edentulous or partially edentulous to such an extent that their masticatory function is significantly impaired (Adell et al 1981). Conventional dentures or prostheses are the traditional method of treatment for edentulism, but they are often inadequate in restoring full masticatory function. Such inadequate restoration of function has negative effects on nutrition, physical appearance and self-esteem (Schnitman et al. 1988). These problems generally worsen with age as additional teeth are lost and alveolar bone resorbs, decreasing the stability and functionality of conventional dentures (Capilouto et Douglass 1988).
Endosseous oral implants are devices that can be inserted into the jawbone, in which they can osseointegrate (Branemark et al. 1977). Oral implants are already available for 30 years. Osseointegration is the direct structural and functional connection between living bone and the surface of a load-bearing implant without the interposition of soft tissue (Albrektsson et al. 1983; Branemark et al. 1985). Such prosthetic constructions supported by implants offer long-term success for periods of 20 years and more in the rehabilitation of edentulous patients (Hansson et al. 1983; Lambrecht et al. 2003; Lindquist et al. 1987; Szmukler-Moncler et al. 2000).
Implant mechanical stability has been identified as an essential criterion for achieving and maintaining osseointegration (Albrektsson et al. 1983;Branemark et al. 1985; Glauser et al. 2004). Several techniques and tools have been proposed to assess stability (Meredith et al. 1996; Olive & Aparicio,C. 1990). However, not all offer sufficient reliability, reproducibility and precision. Moreover, implant planning has witnessed a great leap forward with the introduction of CT based planning. But even though bone density (commonly referred to as bone quality in the literature) as well as bone quantity have to be taken into account, bone density is still neglected during the selection of patients and planning of the implant treatment. It is the aim of this project to investigate implant mechanical stability. The common tools used for that purpose will be evaluated (Implant stability quotient (Osstell ®) and damping capacity (Periotest ®)). Moreover, particular attention will be given to the investigation of the relation of bone quality (ex: in osteoporotic patients) and implant stability, and to the role of bone density in determining the stability of an implant.status: Publishe
A Prospective, Controlled, Multicenter Study to Evaluate the Clinical Outcome of Implant Treatment in Women with Osteoporosis/Osteopenia: 5-Year Results
No full textThe impact of osteoporosis on implant treatment is still a matter of debate in the scientific community, as it may possibly lead to higher failure rates. As long-term controlled trials are missing, the aim of this study was to verify the long-term outcome of implants placed in patients with systemic osteoporosis. Postmenopausal women in need of implants underwent bone mineral density measurements in hip and spine, using dual X-ray absorptiometry scans. Based on T-scores, they were divided into 2 groups: group O (osteoporosis group) with a T-score ≤-2 or group C (control group) with a T-score of ≥-1. Implants were placed in a 2-stage manner and loaded 4 to 8 wk after abutment surgery. Six months after loading and thereafter yearly, clinical and radiographical parameters were assessed. In total, 148 implants were placed in 48 patients (mean age: 67 y [range, 59-83]). Sixty-three implants were placed in 20 patients (group O) and 85 implants in 28 patients (group C). After 5 y, 117 implants (38 in group O and 79 in the group C) in 37 patients were assessed. Cumulative survival rate on an implant level was 96.5% (group O: 91.5%; group C: 100.0% [ P 0.05]) on a patient level. The overall marginal bone-level alterations, after 5 y of loading, were -0.09 ± 0.78 mm (group O: -0.15 ± 0.50 mm; group C: -0.06 ± 0.89 mm) on an implant level and -0.09 ± 0.54 mm (group O: -0.18 ± 0.43 mm; group C: 0.06 ± 0.58 mm) on a patient level ( P > 0.05). Oral implant therapy in osteoporotic patients is a reliable treatment option with comparable osseointegration rates, implant survival, and marginal bone-level alterations after 5 y of functional loading (ClinicalTrials.gov NCT00745121).sponsorship: Prof. Steven Boonen (deceased May 2013, Leuven), Dan Mellstrom (Gothenburg), Osten Ljunggren (Uppsala), Peter Schneider (Wurzburg), and their personnel at the DXA clinics are greatly acknowledged for performing the DXA examinations in this study. A special thank you is addressed to Prof. Hans Mallmin at the Osteoporosis Unit of the University of Uppsala for executing the central reading of the DXA scans. This multicenter study was fully funded by DentsplySirona Implants, Molndal, Sweden. Dr. Temmerman, Dr. Kubler, Dr. Rasmusson, Dr. Merheb, Dr. Thor, and Dr. Quirynen report grants from DentsplySirona Implants during the conduct of the study and outside the submitted work. The authors declare no other po tential conflicts of interest with respect to the authorship and/or publication of this article. (DentsplySirona Implants, Molndal, Sweden, DentsplySirona Implants)status: Publishe
Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers
No full textIncreasing potassium intake ameliorates blood pressure (BP) and cardiovascular (CV) prognoses in the general population; therefore the World Health Organization recommends a high-potassium diet (90–120 mEq/day). Hyperkalaemia is a rare condition in healthy individuals due to the ability of the kidneys to effectively excrete dietary potassium load in urine, while an increase in serum K+ is prevalent in patients with chronic kidney disease (CKD). Hyperkalaemia prevalence increases in more advanced CKD stages, and is associated with a poor prognosis. This scenario generates controversy on the correct nutritional approach to hyperkalaemia in CKD patients, con-sidering the unproven link between potassium intake and serum K+ levels. Another concern is that drug-induced hyperkalaemia leads to the down-titration or withdrawal of renin-angiotensin system inhibitors (RASI) and mineralocorticoids receptors antagonists (MRA) in patients with CKD, de-priving these patients of central therapeutic interventions aimed at delaying CKD progression and decreasing CV mortality. The new K+-binder drugs (Patiromer and Sodium-Zirconium Cyclosili-cate) have proven to be adequate and safe therapeutic options to control serum K+ in CKD patients, enabling RASI and MRA therapy, and possibly, a more liberal intake of fruit and vegetables
- …
